(Q45797972)

16 December 2017

editorial

0 references

title

Interpreting the results of Parkinson's disease clinical trials: time for a change (English)

1 reference

16 December 2017

1 reference

2

John G Nutt

1 reference

16 December 2017

Nick H G Holford

1

1 reference

16 December 2017

language of work or name

English

0 references

publication date

2 March 2011

1 reference

16 December 2017

published in

Movement Disorders

1 reference

16 December 2017

volume

26

1 reference

16 December 2017

issue

4

1 reference

16 December 2017

page(s)

569-577

1 reference

16 December 2017

Levodopa and the progression of Parkinson's disease

cites work

1 reference

A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa

21 January 2018

1 reference

Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease

21 January 2018

1 reference

A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease

21 January 2018

1 reference

A double-blind, delayed-start trial of rasagiline in Parkinson's disease

21 January 2018

1 reference

A mathematical model of pathogenesis in idiopathic parkinsonism

21 January 2018

1 reference

"Disease-modification" trials in Parkinson disease: target populations, endpoints and study design

21 January 2018

1 reference

TORCH and UPLIFT: what has been learned from the COPD "mega-trials"?

21 January 2018

1 reference

Pirfenidone in idiopathic pulmonary fibrosis

21 January 2018

1 reference

Methodologic aspects of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine.

21 January 2018

1 reference

Dyskinesia and the antiparkinsonian response always temporally coincide: a retrospective study

21 January 2018

1 reference

Disease progression, drug action and Parkinson's disease: why time cannot be ignored

21 January 2018

1 reference

The response to levodopa in Parkinson's disease: imposing pharmacological law and order

21 January 2018

1 reference

Learning versus confirming in clinical drug development

21 January 2018

1 reference

Disease progression and pharmacodynamics in Parkinson disease - evidence for functional protection with levodopa and other treatments.

21 January 2018

1 reference

Statistics notes: variables and parameters

21 January 2018

1 reference

Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models

21 January 2018

1 reference

Modeling the short- and long-duration responses to exogenous levodopa and to endogenous levodopa production in Parkinson's disease

21 January 2018

1 reference

Results and validation of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine

21 January 2018

1 reference

Pharmacokinetic/pharmacodynamic modeling in drug development

21 January 2018

1 reference

Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson's disease

21 January 2018

1 reference

Endpoints and analyses to discern disease-modifying drug effects in early Parkinson's disease

21 January 2018

1 reference

Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial

21 January 2018

1 reference

Evolution of the response to levodopa during the first 4 years of therapy.

21 January 2018

1 reference

Pharmacokinetic and pharmacodynamic changes during the first four years of levodopa treatment in Parkinson's disease

21 January 2018

1 reference

Non-linearity of Parkinson's disease progression: implications for sample size calculations in clinical trials

21 January 2018

1 reference

Longitudinal progression of sporadic Parkinson's disease: a multi-tracer positron emission tomography study

21 January 2018

1 reference

The oxidant stress hypothesis in Parkinson's disease: evidence supporting it

21 January 2018

1 reference

Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L-DOPA.

21 January 2018

1 reference

Clinical trial simulation: a review

21 January 2018

1 reference

Impact of pharmacometrics on drug approval and labeling decisions: a survey of 42 new drug applications

21 January 2018

1 reference

Leveraging prior quantitative knowledge to guide drug development decisions and regulatory science recommendations: impact of FDA pharmacometrics during 2004-2006.

21 January 2018

1 reference

Proposals for model-based paediatric medicinal development within the current European Union regulatory framework

21 January 2018

1 reference

Statisticians and pharmacokineticists: what they can still learn from each other.

21 January 2018

1 reference

The delayed-start study design.

21 January 2018

1 reference

More efficient clinical trials through use of scientific model-based statistical tests

21 January 2018

1 reference

A joint model for nonlinear longitudinal data with informative dropout

21 January 2018

1 reference

Assessing and interpreting treatment effects in longitudinal clinical trials with missing data

21 January 2018

1 reference

MMRM vs. LOCF: a comprehensive comparison based on simulation study and 25 NDA datasets

21 January 2018

1 reference

Analysis of treatment effectiveness in longitudinal observational data

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/MDS.23555

1 reference

16 December 2017

1 reference

16 December 2017